Skip to content
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
Read more about the article Psychedelic Therapy isn’t Fringe Anymore

Psychedelic Therapy isn’t Fringe Anymore

  • Post author:Olly PP
  • Post published:October 22, 2022
  • Post category:Industry News

Continue ReadingPsychedelic Therapy isn’t Fringe Anymore
Read more about the article Can Psychedelics Cure?

Can Psychedelics Cure?

  • Post author:Olly PP
  • Post published:October 22, 2022
  • Post category:Industry News

Continue ReadingCan Psychedelics Cure?
Read more about the article The Lancet Commission on Ending Stigma and Discrimination in Mental Health

The Lancet Commission on Ending Stigma and Discrimination in Mental Health

  • Post author:Olly PP
  • Post published:October 22, 2022
  • Post category:Industry News

Continue ReadingThe Lancet Commission on Ending Stigma and Discrimination in Mental Health
Read more about the article The MHRA’s Innovation Passport

The MHRA’s Innovation Passport

  • Post author:Olly PP
  • Post published:October 12, 2022
  • Post category:Industry News

Continue ReadingThe MHRA’s Innovation Passport
Read more about the article Can Psilocybin Challenge Our Pharmaceutical Dependence?

Can Psilocybin Challenge Our Pharmaceutical Dependence?

  • Post author:Olly PP
  • Post published:October 12, 2022
  • Post category:Industry News

Continue ReadingCan Psilocybin Challenge Our Pharmaceutical Dependence?
Read more about the article The Magic Mushroom Experience: Taking Psilocybin for Science

The Magic Mushroom Experience: Taking Psilocybin for Science

  • Post author:Olly PP
  • Post published:October 10, 2022
  • Post category:Industry News

Continue ReadingThe Magic Mushroom Experience: Taking Psilocybin for Science
Read more about the article The Psychedelic Remedy for Chronic Pain

The Psychedelic Remedy for Chronic Pain

  • Post author:Olly PP
  • Post published:September 28, 2022
  • Post category:Industry News

Continue ReadingThe Psychedelic Remedy for Chronic Pain
Read more about the article Psychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer

Psychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer

  • Post author:Olly PP
  • Post published:September 27, 2022
  • Post category:Industry News

Continue ReadingPsychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer
Read more about the article Psilocybin-Assisted Psychotherapy Treatment with Alcohol Use Disorder: A Randomized Clinical Trial

Psilocybin-Assisted Psychotherapy Treatment with Alcohol Use Disorder: A Randomized Clinical Trial

  • Post author:Olly PP
  • Post published:August 24, 2022
  • Post category:Industry News

Continue ReadingPsilocybin-Assisted Psychotherapy Treatment with Alcohol Use Disorder: A Randomized Clinical Trial
Read more about the article Psychedelic Drugs Global Market to Reach $7.03 Billion by 2026

Psychedelic Drugs Global Market to Reach $7.03 Billion by 2026

  • Post author:Olly PP
  • Post published:August 8, 2022
  • Post category:Industry News

Continue ReadingPsychedelic Drugs Global Market to Reach $7.03 Billion by 2026
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Go to the next page

Recent Posts

  • Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors
  • Albert Labs Management and Board of Director Announcement
  • Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology
  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement

Recent Comments

  • Randal Elliott on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Nicholas Stewart on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Camille Ortega on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Kelly Lambert on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Dean Phillips on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2024 Albert Labs. All Rights Reserved

  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact [email protected]

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

  • This field is for validation purposes and should be left unchanged.
Twitter
Youtube
Linkedin
Instagram
Envelope
Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok